Clinical trials: Cancer Head &Neck
Head and Neck Cancer, Mucositis
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
RATIONALE: Growth factors, such as palifermin, may lessen the severity of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
- Trial name
- NCT00360971
- Testing
- palifermin, cisplatin, neck dissection
- Where
- 48 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Cancer, Esophagogastric Junction Cancer
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer…
- Trial name
- NCT04752358
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 3 people
- Sponsor
- Adaptimmune
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
This phase II trial studies how well nivolumab, carboplatin, and paclitaxel work in treating patients with stage III-IV head and neck squamous cell carcinoma that can be removed by surgery.
- Conditions
- Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03342911
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neoplasms, Head and Neck
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based…
- Trial name
- INDUCE-4 (NCT04428333)
- Testing
- Feladilimab, Pembrolizumab, Platinum based chemotherapy
- Where
- 71 sites in United States, Argentina and 17 more
- Volunteers
- 117 people
- Sponsor
- GlaxoSmithKline
Bronchial Dysplasia, Tobacco Smoking
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the…
- Conditions
- Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
- Trial name
- NCT03347838
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Malignant Glioma, Hepatocellular Carcinoma
Early-Phase Safety of Proton Therapy Equipment
The main purpose of this study is to collect the safety data of Sumitomo Heavy Industries' proton therapy equipment for the treatment of solid cancer patients in Linkou Chang Gung Memorial Hospital, including the patients'…
- Conditions
- Malignant Glioma, Hepatocellular Carcinoma, Head and Neck Malignant Tumor, Prostate Cancer
- Trial name
- NCT02315989
- Testing
- proton therapy
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Neoplasms
Development and Evaluation of Rehabilitation Consult for Survivors of Head and Neck Cancer
Although evidence exists to support cancer rehabilitation, services are fragmented and rehabilitation professionals are consulted infrequently and often long after treatment ends, when chronicity of problems limits the impact of…
- Trial name
- HNC-RC (NCT02836769)
- Testing
- Rehabilitation Consult (RC)
- Where
- 2 sites in Canada
- Volunteers
- 35 people
- Sponsor
- Sunnybrook Health Sciences Centre
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by…
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- AcceleRET-Lung (NCT04222972)
- Testing
- Pralsetinib, Carboplatin, Cisplatin
- Where
- 74 sites in Argentina, Australia and 20 more
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8
- Trial name
- NCT05316688
- Testing
- Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Head and Neck Cancer
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for Squamous Cell Carcinoma of the oral cavity.
- Trial name
- NCT02919683
- Testing
- Nivolumab, Ipilimumab, Standard of Care Surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of the Head and Neck
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
This is a research study that plans to learn more about the safety and tolerability of an investigational drug called Olaparib, in combination with radiation therapy and cetuximab.
- Trial name
- NCT01758731
- Testing
- Olaparib, Cetuximab, Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Barrett Esophagus, Esophageal Cancer
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus
This randomized phase II trial studies how well metformin hydrochloride works in preventing esophageal cancer in patients with Barrett esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Trial name
- NCT01447927
- Testing
- metformin hydrochloride
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasm, Goiter
Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
To assess the pain relief and the hemodynamic stability of ropivacaine with epinephrine in BABA endoscopic and robotic thyroidectomy.
- Trial name
- REBT (NCT02112370)
- Testing
- Ropivacaine with epinephrine injection
- Where
- 2 sites in South Korea
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Therapeutic Patient Education, Immune Checkpoint Inhibitors
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI
- Conditions
- Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer
- Trial name
- EDHITO (NCT03948724)
- Testing
- Therapeutic education program, Usual Information
- Where
- 9 sites in France
- Volunteers
- 412 people
- Sponsor
- Institut Cancerologie de l'Ouest
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Trial name
- NCT00625846
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for larynx cancer.
- Trial name
- NCT02759575
- Testing
- Pembrolizumab, Radiation Therapy, Cisplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vinita Takiar
Mouth Neoplasms, Oropharyngeal Neoplasms
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early…
- Conditions
- Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00721799
- Testing
- 18F-Fluorothymidine PET scan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.